46 results about "Immune signaling" patented technology

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment andimmune signal delivery function.

The invention belongs to the technical field of biology, and relates to application of BRI1 in plant immune signal verification and a method. The plant development related regulatory gene BRI1 is applied to plant immune signal verification for the first time. The immune function receptor protein and the receptor protein BRI1 are recombined to construct a recombinant protein; the recombinant protein can be specifically combined with exogenous PAMPs molecules and activate the expression of an arabidopsis thaliana development related reporter gene, and the immunostimulatory activity of the PAMPsmolecules to be detected is determined through the expression quantity of the reporter gene. According to the method, the boundary of plant immunity and development research is broken through, quantitative analysis of the activation capacity of a single immune signal on receptor protein of brassinolide is achieved by detecting brassinolide related signals under the condition that multiple excitonsexist, effectiveness of different immune elements in the multi-antigen recombinant immune protein can be effectively verified. And a new technical means is provided for action mechanism research andbotanical research of recombinant immune protein.

Immune-polyelectrolyte multilayers (iPEMs) that can be made entirely from immune signal compounds are provided. The iPEMs are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound. The immune signal compounds are peptides, polypeptides, nucleic acids, charged derivatives thereof. Combinations of the immune signal compounds may be in adjacent layers. The first immune signal compound and the second immune signal compound have oppositely charged domains. iPEMs can be formed on or include a substrate, such as a sacrificial substrate, which allows for the formation of a three-dimensional void which can hold various other compounds for use in modulating immune responses. The iPEMs are for use in either stimulating an immune response to one or more antigens, or inducing tolerance to one or more antigens. Methods of stimulating immune responses, or inducing tolerance using the iPEMs, are also provided.

The invention belongs to the technical field of medicine, and specifically relates to applications of cyclic dinucleotide cGAMP in preparation of health products. According to the present invention, the research results show that the cyclic dinucleotide cGAMP as the human body natural immune signal pathway activator and the natural immune system enhancer can achieve the important disease preventing and body building immune defense effects of multiple virus infection prevention, tumor occurrence and development inhibition, Alzheimer disease prevention and the like by enhancing the immunity of the innate immune system; the acute animal toxicity test results show that the cGAMP does not present the significant acute toxicity, such that the cGAMP used as the endogenous second messenger capable of regulating the natural immune reaction has potential applications of virus infection prevention, virus infection resistance and tumor resistance; and the cGAMP can be used for preparing the additive of health products or special dietary.

The invention discloses a novel dengue fever microneedle vaccine and a preparation method thereof. The inactivated virus vaccine is prepared by virus culture, virus concentration, virus inactivation and the like, and the novel dengue fever microneedle vaccine is prepared by preparing a reversing mold, preparing a microneedle and the like. The soluble microneedle painless vaccine prepared by the method cannot cause pain, and is safer than subcutaneous injection. The inactivated antigen is injected into muscle by a syringe, and is delivered into skin rich in immune signaling cells by means of microneedle injection, and a better vaccine delivery effect is achieved. The solid-state microneedle coated medicine can be stored at room temperature without refrigeration, and the transportation and storage cost can be greatly reduced in comparison with those of liquid injection medicines.

The present invention provides a cell strain and a detection method for detecting the activity of an antibody-immune agonist conjugated drug. ‑Immune agonist receptors and immune signaling pathway reporter genes in immune agonist drug conjugates. The cell line of the present invention can be used for the activity detection of different target antigens and immune agonist conjugated drugs with different activity levels. The detection method of the present invention can overcome the shortcomings of the co-culture method of PBMC and antigen-positive cells, and has the advantages of simple operation, low cost, higher sensitivity, larger detection dynamic range, and the like, and the antibody obtained by the detection method of the present invention has the advantages of ‑The activity results of the immune agonist-conjugated drug are closer to the results of in vivo efficacy experiments.

Compositions and methods for multispecific protein complexes comprising: an interleukin-15 (IL-15) domain (IL-15N72D) comprising a mutation of N72D, an IL-15 receptor [alpha] suhi-binding domain (IL-15R [alpha] Su), an immunoglobulin Fc domain, and a mutated transforming growth factor-[beta] receptor type 2 (TGF [beta] RII) domain, wherein the mutated TGF [beta] RII domain has N-> Q mutations at positions 47, 71 and 131, respectively. The IL-15R [alpha] Su structural domain, the Fc structural domain and the mutant TGF [beta] RII structural domain are sequentially connected through amido bonds. Preferably, the complexes contemplated further comprise a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule or an immune signaling molecule.

The invention belongs to the field of biotechnology, and relates to the application and method of BRI1 in the verification of plant immune signals. In the present invention, the plant development-related regulatory gene BRI1 is applied to the verification of plant immune signals for the first time. The recombinant protein was constructed by recombining the immune function receptor protein and the receptor protein BRI1; the recombinant protein can specifically bind to exogenous PAMPs molecules and activate the expression of Arabidopsis development-related reporter genes. To measure the immune stimulating activity of PAMPs molecules. The method of the invention breaks the boundaries of plant immunity and development research, and realizes the quantitative analysis of the activation ability of a single immune signal to its receptor protein under the condition of the presence of multiple elicitors by examining the brassinosteroid-related signals, which can effectively The verification of the effectiveness of different immune components in the multi-antigen recombinant immune protein provides a new technical means for the study of the mechanism of action of the recombinant immune protein and botany research.

The invention discloses a method for preparing and identifying the activity of the porcine second messenger molecule 2'3'-cGAMP. The present invention prepares soluble expressed recombinant porcine 2'3'-cGAMP synthetase pcGAS, and then provides a simple, rapid, low-cost, mild condition, high yield and large-scale production of 2'3'-cGAMP The preparation method; meanwhile, a method capable of identifying the biological activity of the recombinant pcGAS enzyme and its catalyzed product 2'3'-cGAMP is provided. The 2'3'-cGAMP prepared by the present invention is an effective activator of the key molecule STING in the natural immune signaling pathway, which can quickly activate and enhance the natural immune response of the host; Biological activities such as tumors, immune enhancement and immune adjuvants have great prospects for the development of drugs, immune enhancers and immune adjuvants.